CYP3A5 Polymorphism in Mexican Renal Transplant Recipients and its Association with Tacrolimus Dosing-Reference-Cited by-同舟云学术

CYP3A5 Polymorphism in Mexican Renal Transplant Recipients and its Association with Tacrolimus Dosing

Published:2012-05 Issue:4 Volume:43 Page:283-287
ISSN:0188-4409
Container-title:Archives of Medical Research
language:en
Short-container-title:Archives of Medical Research

Author:

García-Roca Pilar,Medeiros Mara,Reyes Herlinda,Rodríguez-Espino Benjamín Antonio,Alberú Josefina,Ortiz Lourdes,Vásquez-Perdomo Mayela,Elizondo Guillermo,Morales-Buenrostro Luis Eduardo,Mancilla Urrea Eduardo,Castañeda-Hernández Gilberto

Publisher

Elsevier BV

Subject

General Medicine

Reference33 articles.

1. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection;Marcen;Drugs,2009

2. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil;Millan;Clin Chem,2003

3. Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus;Park;Fundam Clin Pharmacol,2009

4. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome;Mourad;Transplantation,2008

5. Simulation of sirolimus exposures and population variability immediately post renal transplantation: importance of the patient’s CYP3A5 genotype in tailoring treatment;Lukas;Biopharm Drug Dispos,2010

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant;Genes;2024-04-16

2. Pharmacogenomic implications of the differential distribution of CYP3A5 metabolic phenotypes among Latin American populations;Pharmacogenomics;2024-03

3. Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients;Clinical and Translational Science;2023-06-26

4. Evaluation of limited-sampling strategies to calculate AUC(0–24) and the role of CYP3A5 in Chilean pediatric kidney recipients using extended-release tacrolimus;Frontiers in Pharmacology;2023-03-14

5. Predictive Capacity of Population Pharmacokinetic Models for the Tacrolimus Dose Requirements of Pediatric Solid Organ Transplant Recipients;Therapeutic Drug Monitoring;2023-02